Low molecular weight amidoximes that act as potent inhibitors of lysine-specific demethylase 1.

The recently discovered enzyme lysine-specific demethylase 1 (LSD1) plays an important role in the epigenetic control of gene expression, and aberrant gene silencing secondary to LSD1 dysregulation is thought to contribute to the development of cancer. We reported that (bis)guanidines, (bis)biguanides, and their urea- and thiourea isosteres are potent inhibitors of LSD1 and induce the re-expression of aberrantly silenced tumor suppressor genes in tumor cells in vitro. We now report a series of small molecule amidoximes that are moderate inhibitors of recombinant LSD1 but that produce dramatic changes in methylation at the histone 3 lysine 4 (H3K4) chromatin mark, a specific target of LSD1, in Calu-6 lung carcinoma cells. In addition, these analogues increase cellular levels of secreted frizzle-related protein (SFRP) 2, H-cadherin (HCAD), and the transcription factor GATA4. These compounds represent leads for an important new series of drug-like epigenetic modulators with the potential for use as antitumor agents.

[1]  Min Gyu Lee,et al.  Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. , 2006, Chemistry & biology.

[2]  S. Baylin,et al.  Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? , 2006, Nature Reviews Cancer.

[3]  Wei Liu,et al.  Reconstitution of Secreted Frizzled-Related Protein 1 Suppresses Tumor Growth and Lung Metastasis in an Orthotopic Model of Hepatocellular Carcinoma , 2010, Digestive Diseases and Sciences.

[4]  Andrew J. Bannister,et al.  Unsafe SETs: histone lysine methyltransferases and cancer. , 2002, Trends in biochemical sciences.

[5]  T. Kouzarides.  Histone methylation in transcriptional control. , 2002, Current opinion in genetics & development.

[6]  Gen-Bao Shao,et al.  Role of histone methylation in zygotic genome activation in the preimplantation mouse embryo , 2008, In Vitro Cellular & Developmental Biology - Animal.

[7]  Matthew W Vaughn,et al.  The Fission Yeast Jmj2 Reverses Histone H3 Lysine 4 Trimethylation* , 2007, Journal of Biological Chemistry.

[8]  Yang Shi,et al.  Reversal of Histone Lysine Trimethylation by the JMJD2 Family of Histone Demethylases , 2006, Cell.

[9]  Yi Zhang,et al.  Purification of histone demethylases from HeLa cells. , 2006, Methods.

[10]  F. Forneris,et al.  Structural Basis of LSD1-CoREST Selectivity in Histone H3 Recognition* , 2007, Journal of Biological Chemistry.

[11]  T. Jenuwein.  The epigenetic magic of histone lysine methylation , 2006, The FEBS journal.

[12]  Takayoshi Suzuki,et al.  Synthesis and biological activity of optically active NCL-1, a lysine-specific demethylase 1 selective inhibitor. , 2011, Bioorganic & medicinal chemistry.

[13]  V. Richon,et al.  Histone deacetylase inhibitors as new cancer drugs , 2001, Current opinion in oncology.

[14]  H. Timmers,et al.  Histone lysine methylation and demethylation pathways in cancer. , 2011, Biochimica et biophysica acta.

[15]  T. Richmond,et al.  Crystal structure of the nucleosome core particle at 2.8 Å resolution , 1997, Nature.

[16]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[17]  Makoto Hasegawa,et al.  Identification of cell-active lysine specific demethylase 1-selective inhibitors. , 2009, Journal of the American Chemical Society.

[18]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[19]  Cyrus Martin,et al.  The diverse functions of histone lysine methylation , 2005, Nature Reviews Molecular Cell Biology.

[20]  P. Cole,et al.  A mechanism-based inactivator for histone demethylase LSD1. , 2006, Journal of the American Chemical Society.

[21]  S. Baylin,et al.  Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes , 2007, Proceedings of the National Academy of Sciences.

[22]  A. Hoelz,et al.  Lysine-specific demethylase 1 as a potential therapeutic target , 2007, Expert opinion on therapeutic targets.

[23]  R. Glen,et al.  Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. , 1995, Journal of molecular biology.

[24]  Shiv k. Sharma,et al.  (Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators. , 2010, Journal of medicinal chemistry.

[25]  Jingjing Ji,et al.  1,3-Dinitro-2-chloro-5-trifluorotoluene and its bridged derivatives I. An investigation on the displacement reactions of bidentate nucleophiles towards aromatic rings , 2010 .

[26]  Michael A. Freitas,et al.  Identification of novel histone post-translational modifications by peptide mass fingerprinting , 2003, Chromosoma.

[27]  S. Toyooka,et al.  Aberrant methylation of the CDH13 (H-cadherin) promoter region in colorectal cancers and adenomas. , 2002, Cancer research.

[28]  A. Mai,et al.  Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. , 2010, Journal of the American Chemical Society.

[29]  Ricky W. Johnstone,et al.  Histone-deacetylase inhibitors: novel drugs for the treatment of cancer , 2002, Nature Reviews Drug Discovery.

[30]  D. M. Schmidt,et al.  trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. , 2007, Biochemistry.

[31]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[32]  M. Anderson,et al.  CoREST: a functional corepressor required for regulation of neural-specific gene expression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  P. Woster,et al.  Structural comparison of alkylpolyamine analogues with potent in vitro antitumor or antiparasitic activity , 1996 .

[34]  Peter A. Jones,et al.  Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Tony Kouzarides,et al.  Histone H3 lysine 4 methylation patterns in higher eukaryotic genes , 2004, Nature Cell Biology.

[36]  Steven J. Gamblin,et al.  Crystal Structure and Functional Analysis of the Histone Methyltransferase SET7/9 , 2002, Cell.

[37]  Min Gyu Lee,et al.  An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation , 2005, Nature.

[38]  S. Hecht,et al.  Search for Cyclodextrin-Based Inhibitors of Anthrax Toxins: Synthesis, Structural Features, and Relative Activities , 2006, Antimicrobial Agents and Chemotherapy.

[39]  Hui Zhang,et al.  Histone Deacetylase Inhibitor Depsipeptide Activates Silenced Genes through Decreasing both CpG and H3K9 Methylation on the Promoter , 2008, Molecular and Cellular Biology.

[40]  P. Woster,et al.  Properties of purified recombinant human polyamine oxidase, PAOh1/SMO. , 2003, Biochemical and biophysical research communications.

[41]  Takayoshi Suzuki,et al.  Lysine demethylases inhibitors. , 2011, Journal of medicinal chemistry.

[42]  D. Ward,et al.  Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. , 2011, Cancer research.

[43]  P. Woster,et al.  Novel alkylpolyaminoguanidines and alkylpolyaminobiguanides with potent antitrypanosomal activity. , 2006, Bioorganic & medicinal chemistry letters.

[44]  S. Baylin,et al.  Novel Oligoamine Analogues Inhibit Lysine-Specific Demethylase 1 and Induce Reexpression of Epigenetically Silenced Genes , 2009, Clinical Cancer Research.

[45]  D. Reinberg,et al.  Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. , 2001, Genes & development.

[46]  Yong Chen,et al.  Crystal structure of human histone lysine-specific demethylase 1 (LSD1) , 2006, Proceedings of the National Academy of Sciences.

[47]  Tony Kouzarides,et al.  Reversing histone methylation , 2005, Nature.